David Vidal

Contributor   in
Emerging Technologies  

I received my Ph.D. in Organic Chemistry from the University of Barcelona in 2006. Throughout my career, I have participated in many computational drug discovery projects and contributed to the development of a wide range of modeling tools. Currently, I lead the R&D department at Mind the Byte, a multidisciplinary team of scientists and software engineers committed to the development of our drug discovery SaaS platform. Our main research lines include the development of new and effective in silico pharmacology tools and the application of machine learning for the improvement of traditional CADD techniques.

tags:   ADMET     Artificial Intelligence     Docking     In Silico     QSAR    

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

Artificial Intelligence For Drug Discovery Use Cases At Mind the Byte

Artificial Intelligence For Drug Discovery Use Cases At Mind the Byte

UPDATE: Mind the Byte ceased operations and was liquidated in 2019.

Artificial intelligence (AI) has become a hot topic in the biopharmaceutical environment and nearly every pharma company in the world has embraced it hoping that it will play a major role in speeding up drug discovery, by reducing R&D costs and avoiding failure in late development stages. According to prospects, AI-driven drug discovery will lead to the development of new and more effective drugs, paving thus the way to personalized medicine.